tm
Seeing Is Believing
tm
Seeing Is Believing
Currently out of the existing stock ratings of Ravi Mehrotra, 5 are a BUY (100%).
Analyst Ravi Mehrotra, carries an average stock price target met ratio of 100% that have a potential upside of 24.3% achieved within 100 days.
Ravi Mehrotra’s has documented 10 price targets and ratings displayed on 2 stocks. The coverage was on the Healthcare sector.
Most recent stock forecast was given on BIIB, Biogen at 19-Nov-2014.
Analyst best performing recommendations are on BIIB (BIOGEN).
The best stock recommendation documented was for BIIB (BIOGEN) at 11/22/2013. The price target of $290 was fulfilled within 3 days with a profit of $4.38 (1.53%) receiving and performance score of 5.11.
Average potential price target upside
Analyst name
Rating
Current price target
Potential Upside
Previous price target
Date of last PT
Price targets met ratio
Average potential upside
Average Days to Hit Target
Performance score
Hold Since 20-Feb-2026
$185
$0.13 (0.07%)
21 days ago
(20-Feb-2026)
8/9 (88.89%)
$-7.08 (-3.69%)
345
Hold Since 22-May-2019
$187
$2.13 (1.15%)
$121
1 months 3 days ago
(10-Feb-2026)
28/31 (90.32%)
$-1.99 (-1.05%)
177
Buy Since 03-Mar-2022
$233
$48.13 (26.03%)
$210
1 months 4 days ago
(09-Feb-2026)
39/74 (52.7%)
$39.19 (20.22%)
121
Buy Since 01-May-2023
$246
$61.13 (33.07%)
$165
1 months 4 days ago
(09-Feb-2026)
12/15 (80%)
$52.19 (26.93%)
319
Buy Since 27-Jan-2020
$230
$45.13 (24.41%)
$220
1 months 4 days ago
(09-Feb-2026)
14/28 (50%)
$36.19 (18.67%)
228
What Year was the first public recommendation made by Ravi Mehrotra?
